Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type b vaccine experience
- 12 October 2011
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions Of The Royal Society B-Biological Sciences
- Vol. 366 (1579), 2827-2832
- https://doi.org/10.1098/rstb.2011.0046
Abstract
Adoption of new vaccines in developing countries is critical to reducing child mortality and meeting Millennium Development Goal 4. However, such introduction has historically suffered from significant delays that can be attributed to various factors including (i) lack of recognition of the value of a vaccine, (ii) factors related to weak health systems, and (iii) policy considerations. Recently, the Global Alliance for Vaccines and Immunization (GAVI) supported efforts to accelerate the introduction of Haemophilus influenzae type b (Hib) vaccines in developing countries, which resulted in a significant surge in vaccine adoption by these countries. The experience with Hib vaccines, as well as similar efforts by GAVI to support the introduction of new pneumococcal and rotavirus vaccines, provides a strategy for new vaccine adoption that is reviewed in this paper, providing a useful model to help accelerate the uptake of other life-saving vaccines. This strategy addresses barriers for vaccine adoption by focusing on three major areas: (i) communications to increase awareness about the various factors needed for evidence-based decisions that meet a country's health goals; (ii) research activities to answer key questions that support vaccine introduction and long-term programme sustainability; and (iii) coordination with the various stakeholders at global, regional and country levels to ensure successful programme implementation.Keywords
This publication has 20 references indexed in Scilit:
- Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experienceVaccine, 2010
- Global, regional, and national causes of child mortality in 2008: a systematic analysisThe Lancet, 2010
- Accelerating Policy Decisions to Adopt Haemophilus influenzae Type b Vaccine: A Global, Multivariable AnalysisPLoS Medicine, 2010
- Letter from the EditorHuman Vaccines, 2010
- Childhood Bacterial Meningitis in Ulaanbaatar, Mongolia, 2002–2004Clinical Infectious Diseases, 2009
- Introducing new vaccines in the poorest countries: What did we learn from the GAVI experience with financial sustainability?Vaccine, 2008
- Progress in Vaccination against Haemophilus influenzae type b in the AmericasPLoS Medicine, 2008
- The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalenceVaccine, 2006
- Effectiveness of Haemophilus influenzae Type b Conjugate Vaccine Introduction Into Routine Childhood Immunization in KenyaJama-Journal Of The American Medical Association, 2006
- Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countriesVaccine, 1999